Selen bei malignen hämatologischen Erkrankungen: von der Zytoprotektion bis zur Apoptoseinduktion

Zusammenfassung

Selen ist ein essenzielles Spurenelement. Es wird spezifisch über einen sehr komplexen Vorgang in Selenoproteine eingebaut. Eine defizitäre Versorgung von Patienten mit Krebserkrankungen wurde mehrfach beschrieben [17]. Der Selenbedarf von onkologischen Patienten nimmt in therapeutischer Belastungssituation erheblich zu, so z. B. während Strahlentherapie, Chemotherapie und in der perioperativen Situation [19]. Neben immer wieder kontrovers diskutierten Untersuchungen, mit teilweise widersprüchlichen Ergebnissen, zur Primärprävention von malignen Erkrankungen, insbesondere des Prostatakarzinoms [7], [20], gibt es zahlreiche internationale Publikationen zum interventionellen Einsatz von Selen, begleitend zur konventionellen Tumortherapie, sowie Untersuchungen aus der Präklinik zum Mechanismus der Wirkungsweise von Selen und verschiedenen Selenmetaboliten bei Tumorerkrankungen. Dabei werden überwiegend therapeutisch synergistische, selektiv zytoprotektive Effekte auf gesunde Zellen und pro-apoptotische Effekte auf maligne Zellen beschreiben. In diesem Beitrag wird der Fokus auf eine aktuelle Übersicht zum Einsatz von Selen bei malignen hämatologischen Erkrankungen gerichtet.

Summary

Selenium is an essential trace element. It is integrated into specific selenoproteins in a sophisticated manner. In several publications a deficiant supply was indicated [17]. The demand for selenium is enhanced in stressfull treatment situations, such as durind radiotherapy, chemotherapy and in peri-operative situations [19]. Besides intensely discussed results of studies, mostly with prostate cancer in the situation of primarily prevention [7], [20] with different forms of selenium, there are numerous international publications in preclinical and clinical setting, examining the mode of action and the effects of selenium and its various metabolites on malignant diseases. Predominantly synergistic therapeutic and selective cytoprotective effects were described. This report is focusing on the application of selenium as sodium selenite with hematologic malignant diseases.

Schlüsselwörter

Selen - Natriumselenit - hämatologische maligne Erkrankungen - Selenmangel - Zytoprotektion - Mukositis - Apoptose - NFkappaB - Lymphom - Leukämie

Keywords

Selenium - sodium selenite - hematologic malignancies - selenium deficiency - zytoprotetction - mucositis - apoptosis - NFkappaB - lymphoma - leukemia

• Literatur

• 1 Asfour I et al Effect of high-dose sodium selenite therapy on polymorphonuclear leucocyte apoptosis in non-hodgkin’s lymphoma patients. Biol Trace Elem Res 2006; 110(1): 19-32
• 2 Asfour IA et al The impact of high-dose sodium selenite therapy on Bcl-2 expression in adult non-Hodgkin’s lymphoma patients: correlation with response and survival. Biol Trace Elem Res 2007; 120 (1−3): 1-10
• 3 Asfour IA et al High-dose sodium selenite can induce apoptosis of lymphoma cells in adult patients with non-Hodgkin’s lymphoma. Biol Trace Elem Res 2009; 127(3): 200-10
• 4 Asfour IA et al Selenium and glutathione peroxidase status in adult Egyptian patients with acute myeloid leukemia. Biol Trace Elem Res 2009; 132(1−3): 85-92
• 5 Azarm T et al Serum selenium levels in chronic lymphocytic leukemia. Adv Biomed Res 2013; 2: 44
• 6 Avanzini P et al Serum selenium concentrations in patients with newly diagnosed lymphoid malignancies. Haematologica 1995; 80: 505-11
• 7 Clark LC et al Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 1996; 276(24): 1957-63
• 8 Hadjibabaie M et al The prevalence of low selenium levels in adult patients undergoing bone marrow transplantation: a brief communication. Nutr Cancer 2008; 60(6): 837-9
• 9 Jahangard-Rafsanjani Z et al The efficacy of selenium in prevention of oral mucositis in patients undergoing hematopoietic SCT: a randomized clinical trial. Bone Marrow Transplant 2013; 48(6): 832-6
• 10 Jüliger S et al Chemosensitization of b-cell lymphomas by methylselenic acid involves nuclear factor kappab inhibition and the rapid generation of other selenium species. Cancer Res 2007; 67(22): 10984-92
• 11 Lanfear J et al The selenium metabolite selenodiglutathione induces p53 and apoptosis: relevance to the chemopreventive effects of selenium?. Carcinogenesis 1994; 15(7): 1387-92
• 12 Last K et al Presentation serum selenium for overall survival, dose delivery and first treatment response in aggressive non-hodgkin-lymphoma. J Clin Oncol 2003; 21(12): 2335-41
• 13 Last K et al The activity of methylated and non-methylated selenium species in lymphoma cell lines and primary tumours. Ann Oncol 2006; 17: 773-79
• 14 López-Lázaro M et al Selenite induces topoisomerase I and II-DNA complexes in K562 leukemia cells. Int J Cancer 2008; 123(9): 2217-21
• 15 Ozgen IT et al Hair selenium status in children with leukemia and lymphoma. J Pediatr Hematol Oncol 2007; 29(8): 519-22
• 16 Radhakrishnan N et al Antioxidant levels at diagnosis in childhood acute lymphoblastic leukemia. Indian J Pediatr 2013; 80(4): 292-6
• 17 Rayman MP. Selenium and human health. Lancet 2012; 379(9822): 1256-68
• 18 Stevens J et al Serum selenium concentrations at diagnosis and outcome in patients with haematological malignancies. Br J Haematol 2011; 154: 448-56
• 19 Stoppe C et al Selenium blood concentrations in patients undergoing elective cardiac surgery and receiving perioperative sodium selenite. Nutrition 2013; 29(1): 158-65
• 20 Vinceti M et al Selenium for preventing cancer. Cochrane Database Syst Rev 2014; 3 CD005195. 
• 21 Zuo XL et al Levels of selenium, zinc, copper, and antioxidant enzyme activity in patients with leukemia. Biol Trace Elem Res 2006; 114(1−3): 41-53